PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week
DAEJEON, South Korea, Dec. 8, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company is invited to participate in upcoming 41th Annual J.P. Morgan Healthcare Conference which will have the partnering meetings arranged through BIO One-on-One Partnering system. The Company...
CereCore® expands healthcare technology services into the UK
CereCore® is hiring EPR, technical and staffing expertise to work with healthcare organizations in the UK and other international locations in order to move patient record digitalisation forward. NASHVILLE, Tenn., Dec. 8, 2022 /PRNewswire/ -- CereCore today announced they are expanding their healthcare information technology (IT) services including electronic patient record (EPR), technical and...
Japanese Healthcare Startup Ubie, Inc. Closes Extended Series C Round at $45 million, Establishes Subsidiary in NY
TOKYO, Dec. 8, 2022 /PRNewswire/ -- Ubie, Inc., a Tokyo-based healthcare startup, announced on December 8 that it has closed its Series C round at $45 million by raising $19 million in an extension round. The new funding will enable Ubie to accelerate its growth and strengthen its presence in the U.S., following strong interest and traction in that...
Createrna Announces Positive Top-Line Results from Phase 1 Clinical Trials of QR052107B Tablet in Healthy Volunteers
QR052107B Tablet was safe and well tolerated in healthy volunteers across all tested doses, with no taste related adverse event at the anticipated therapeutic doses Createrna initiated a clinical Phase 2 trial to study QR052107B Tablet at once-a-day (QD) dose in the treatment of refractory and unexplained chronic cough...
Amway launches Singapore Business Innovation Hub to accelerate health and wellness innovation
Hub launched in partnership with the Economic Development Board to serve as a springboard for product innovation to meet consumers' evolving wellness needs globally and also uniquely in Asia, backed by science and technology SINGAPORE, Dec. 8, 2022 /PRNewswire/ -- Amway, an entrepreneur-led health and wellness company, today announced the opening of its Singapore Business Innovation Hub in the...
Antengene Appoints Amily Zhang as its Chief Medical Officer
SHANGHAI and HONG KONG, Dec. 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, recently announced that Amily Zhang has been appointed as the Company's Chief Medical Officer, succeeding Dr....
HARRISON.AI NAMED ON THE 2022 CB INSIGHTS’ DIGITAL HEALTH 150 LIST
The clinician-led technology platform has been recognized for achievements in computer-aided imaging NEW YORK, Dec. 8, 2022 /PRNewswire/ -- CB Insights today named harrison.ai to its fourth-annual Digital Health 150, showcasing the 150 most promising private digital health companies of 2022. "From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year's Digital Health 150...
BSR KOREA Introduces “Wizbiosolutions Inc.” as “2022 Global Procurement Marketer”
SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- As the practitioner of "2022 Global Procurement Marketer (GPM) Project" promoted by the Ministry of SMEs and Startups (MSS) and Korea SMEs and Startups Agency (KOSME), BSR KOREA offered consultation for 40 domestic SMEs that want to enter the international procurement market, including capacity building...
Lost childhood: a ‘tight-knit’ network to combat abuse and distress
On Radar takes off, the first meeting of the Think Tank of Fondazione Internazionale Menarini ROME, Dec. 7, 2022 /PRNewswire/ -- Setting real changes in motion through dialogue among experts in order to tackle the unresolved issues of juvenile distress. This was the topic addressed during the first meeting of the 'On...
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023 --Phase I clinical trial will also determine if ASC11 needs to be boosted by ritonavir or not --In antiviral cellular assays,...
